Baseline characteristics for INFRONT 3: A Phase 3 double blind, placebo[...]
Notification Letter and Reply Form to Non registered Shareholders[...]
03/20/2023 | Press release | Distributed by Public on 03/19/2023 22:39
Please select the service you want to use:
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact